Best Growth Stocks to Buy for October 13th

The article highlights three Zacks Rank #1 stocks whose current-year consensus earnings estimates rose over the past 60 days: Petco by 26.3%, Five Below by 15.2%, and Oscar Health by 18.8%. It presents them as growth-stock ideas but provides no new company results or share-price reaction.

Analysis

The useful signal here is estimate-revision direction, not the promotional “early price pops” framing. Revisions can support near-term momentum, but without the underlying earnings bridge they do not establish durable earnings growth or attractive valuation; the screen is not a common-factor trade across these three very different businesses.

For Five Below, the key test is whether estimate upgrades reflect sustained traffic, ticket and merchandise margin—or merely easier comparisons. A slowdown in discretionary spending or markdown pressure could reverse revisions quickly. Petco’s upgrade is more exposed to whether operating execution converts into cash generation; estimate improvement alone does not resolve balance-sheet or turnaround risk. For Oscar Health, reported earnings are especially sensitive to medical costs and regulatory/risk-adjustment assumptions, so revisions merit less confidence until supported by medical loss ratio and membership economics.

Near term (days), the article itself is a weak catalyst and any screen-driven buying may fade. Over 1–3 months, look for revisions to persist through results and guidance. Over 6–18 months, competitive positioning and cash conversion matter more than rank labels. Contrarian read: the screen emphasizes recent estimate momentum while omitting revision breadth, valuation, cash flow, and the assumptions behind each forecast. No trade is justified from this evidence alone.

Key Decisions for Investors

• Do not buy the three-stock basket solely on the ranking or estimate-revision percentages; treat it as a watchlist signal, not an earnings-quality screen.
• For FIVE, consider a long only after confirming upgrades are supported by comparable-sales/traffic trends and gross-margin stability; falsify on guidance cuts or sustained markdown pressure.
• For WOOF, require evidence that earnings revisions translate into improving free cash flow and balance-sheet progress before taking turnaround exposure; abandon the thesis if cash generation or guidance deteriorates.
• For OSCR, monitor medical loss ratio, membership mix, and regulatory or risk-adjustment developments before positioning; a rising medical-cost trend or adverse guidance would invalidate the upgrade signal.